Refine your search
32 results found
Taylor Wessing | European Union | 10 May 2023
The European Commission's pharmaceutical reform package: core objectives and planned changes at a glance
The European Commission presented its draft for a comprehensive reform of the pharmaceutical legislation on 26 April 2023. The so-called EU Pharma…
Accura Advokatpartnerselskab | European Union | 28 Apr 2023
Proposed overhaul of regulation of pharmaceuticals in the EU
On 26 April 2023, the EU Commission published its awaited proposals to reform the regulation of pharmaceuticals in the EU. The reform aims to…
Accura Advokatpartnerselskab | Denmark | 28 Apr 2023
Revision of ENLI’s Guidance on the Promotion Code
The Danish Ethical Committee for the Pharmaceutical Industry (ENLI) has issued a revised version of its Guidance on the Promotion Code (the Guidance)…
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | European Union, USA | 26 Jan 2023
IP Issues Surrounding Machine Learning and AI in the Pharmaceutical Space
When it comes to protecting technical innovations there are two broad strategies: keep it a trade secret or obtain a patent. It has long been the…
Van Bael & Bellis | Belgium, Netherlands | 25 Jan 2023
Belgian and Dutch Competition Authorities Aim Again at Pharmaceutical Sector
As if on cue, the Belgian and Dutch competition authorities announced on 24 January 2023 new significant developments with regard to their…
Maiwald GmbH | Germany | 12 Jan 2023
No use as trademark in a company’s own customer loyalty system
According to a decision of the OLG Nuremberg, the use of a sign for a company’s own customer loyalty system does not constitute use as a trademark…
Bristows | European Union, United Kingdom | 28 Nov 2022
European Commissioner Kyriakides hints at decisive action on EU MDR transition period
At the Plenary session of the European Parliament on 24 November, European Commissioner for Health and Food Safety, Stella Kyriakides, indicated that…
Hogan Lovells | Italy | 7 Oct 2022
The Pharma Industry and Investment Arbitration: What chances for foreign Iivestors?
The possibility for pharmaceutical companies to usefully resort to investment arbitration has been until recently shrouded in ambiguity. While the…
Zhong Lun Law Firm | China | 2 Sep 2022
驾驭罕见病药品定价和销售的“三驾马车”（下）——药企数据合规与患者援助项目法律指南
如上篇与中篇所述，尽管过去几年中我国在商业健康保险、医保谈判及行业集采方面获得了令人瞩目的成就，并通过支持创新、降低药物价格和患者援助项目给罕见病…
Moroğlu Arseven | Turkey | 17 Aug 2022
The Bolar Exemption and Data Exclusivity: How They Apply In Turkey
In Turkey, pharmaceutical products for human use cannot be marketed unless they are authorized by the Ministry of Health (“MoH”). In order to grant…
